AI주식인사이트AI Stock Insight
C

지니너스

389030KOSDAQ자연과학 및 공학 연구개발업

42.4 / 100

Reference Date: 2026-06-10

Financial Score10.5 / 40
News Sentiment16.9 / 25
Momentum5.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Plunged 37.5% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Geninus focuses on genomics, bioinformatics, and the development of in-vitro diagnostic medical devices, leveraging advanced technologies such as NGS and PCR to provide innovative healthcare solutions in early cancer detection, liquid biopsy, and precision medicine. The company also conducts research on mutations and biomarkers to support disease prognosis prediction and personalized treatment strategies.

Number of Employees

59people

Average Salary

72.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 62.704.0Point
PBR
10.59Industry Average 3.240.0Point

3.3x industry avg (risky)

ROE
-110.87Industry Average -32.093.5Point

3.5x industry avg (excellent)

Debt Ratio
18.72Industry Average 7.310.0Point

2.6x industry avg (risky)

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲27.5% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼8.4% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -59.7% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 1Neutral 1Negative 0Average Sentiment Score 67.5

Detailed Momentum

52-week position3.0Point

52w lower range (28%)

Current 2,870Won52-week high 6,27052-week low 1,505
1-month return0.0Point

1m -37.47% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

12 totalPositive 0Neutral 12Negative 0
  • Neutral[기재정정]전환청구권행사2026-06-09
  • Neutral[기재정정]전환청구권행사2026-06-09
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-29
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-29
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-29